Cat. #156469
U2OS E2F7 KO cell line
Cat. #: 156469
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-5 days
Organism: Human
Tissue: Bone
Disease: Cancer
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Ana Maria Zubiaga ; Iraia Garcia Santisteban
Institute: University of the Basque Country (EHU)
Tool Details
*FOR RESEARCH USE ONLY
- Name: U2OS E2F7 KO cell line
- Alternate name: U-2 OS
- Tool sub type: Continuous
- Parental cell: U2OS
- Organism: Human
- Tissue: Bone
- Disease: Cancer
- Growth properties: Increased G2/M checkpoint recovery competence and improved viability upon treatment with compounds that affect replication fork progression (cisplatin, mitomycin C, olaparib).
- Model: Knock-Out
- Conditional: No
- Description: E2F7 is a transcription factor that participates in various processes such as cell cycle regulation and DNA damage response by mediating transcriptional repression of target genes involved in G1/S regulation as well as in DNA replication and repair. E2F7 behaves as a tumour suppressor by inhibiting DNA repair activity of tumour cells upon chemotherapy treatment. Loss of E2F7 by CRISPR knockout confers increased resistance to chemotherapy in BRCA2-deficient cells. CRISPR edited U2OS cells.
- Production details: E2F7 knockout cells were generated using the CRISPR/Cas9 system. A CRISPR guide RNA (gRNA) targeting the first coding exon of E2F7 was designed using Benchling, and cloned into the BbsI site of pX330 (42230, Addgene). U2OS cells were co-transfected with this plasmid, together with a plasmid containing a gRNA to the zebrafish TIA gene (5 -GGTATGTCGGGAACCTCTCC3 ) and a P2A-puromycin resistance cassette flanked by two TIA target sites. Co-transfection results in excision of the cassette and subs...
- Biosafety level: 1
- Additional notes: CRISPR edited U2OS cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provid...
- Recommended controls: Parental U2OS cells, puromycin sensitive
Target Details
- Target: Full knockout for the E2F7 gene
Applications
- Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...
Handling
- Format: Frozen
- Growth medium: Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Mitxelena et al. 2018. Nucleic Acids Res. 46(9):4546-4559. PMID: 29590434.
